Core Viewpoint - A securities class-action lawsuit has been filed against Centene Corporation, alleging that the company misrepresented its financial health and market conditions to investors [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, targets investors who purchased Centene securities between December 12, 2024, and June 30, 2025 [1]. - The complaint claims that Centene's leadership provided a misleadingly optimistic view of projected revenue growth, strong enrollment, and low morbidity levels, which contradicted internal data [2]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 financial guidance after an independent actuarial review indicated that market growth was "lower than expected" and morbidity levels were "materially inconsistent" with prior assumptions, leading to a stock price drop of over 40% [3]. - Following the lawsuit, Centene reported a Q2 diluted loss per share of -$0.51, attributed to reduced revenue estimates [4]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights law firm, is investigating claims on behalf of investors who suffered losses, focusing on whether Centene misrepresented its marketplace business health [5]. - The firm encourages whistleblowers with non-public information about Centene to come forward, offering potential rewards of up to 30% of any successful SEC recovery [5].
CNC Investor Update: Lawsuit Filed Against Centene (CNC) Over Enrollment – Hagens Berman